Periodontitis (Stage 3)NCT07851584
Er,Cr:YSGG Laser in Smokers With Stage III Periodontitis
A study testing Nonsurgical Periodontal Therapy and Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser in people with Periodontitis (Stage 3), run by Okan University at 1 site in Turkey (Türkiye).
Trial summary
Periodontitis is an inflammatory disease that affects the tissues supporting the teeth. If the disease progresses, it can cause loss of the tissues and bone around the teeth and lead to the formation of deep spaces, called periodontal pockets, between the teeth and gums. Read more about this study
- Who is it for?
- Ages 35 to 65 years
- Conditions the study is for
- Periodontitis (Stage 3)
- What is being tested?
- Nonsurgical Periodontal Therapy and Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2025to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 35 and 65 years
- Systemically healthy status
- Smoking ≥10 cigarettes/day for at least 5 years
- Diagnosis of Stage III Grade C periodontitis according to the 2017 classification
- Stage III classification based on periodontal tissue destruction, with interdental clinical attachment loss ≥5 mm
- Presence of contralateral study sites suitable for split-mouth allocation, with clinical attachment loss ≥5 mm at both test and control sites
Show all 9Show fewer
- Presence of contralateral interdental regions between premolar teeth, without tooth loss, suitable for split-mouth allocation
- No antibiotic use within the previous 3 months
- No periodontal treatment within the previous 6 months
Who cannot join
- Systemic disease or condition affecting periodontal status, wound healing, or bone metabolism
- Pregnancy or lactation
- Non-smoker or smoking <10 cigarettes/day
- Gingivitis
- Stage I, Stage II, or Stage IV periodontitis
- Grade A or Grade B periodontitis
Show all 10Show fewer
- No suitable contralateral study sites for split-mouth allocation, defined as CAL ≥5 mm and PPD ≥5 mm at both test and control sites
- Tooth loss in the selected interdental regions between premolar teeth planned for test or control allocation
- Antibiotic use within the previous 3 months
- Periodontal therapy within the previous 6 months
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Okan University Faculty of Dentistry Department of Periodontology
Istanbul, Tuzla
About this study
Official title: Clinical, Radiographic, and Biochemical Outcomes of Er,Cr:YSGG Laser-Assisted Nonsurgical Periodontal Therapy in Smokers With Stage III Grade C Periodontitis: A Split-Mouth Randomized Controlled Trial
Periodontitis is an inflammatory disease that affects the tissues supporting the teeth. If the disease progresses, it can cause loss of the tissues and bone around the teeth and lead to the formation of deep spaces, called periodontal pockets, between the teeth and gums. The main treatment for periodontitis is to improve oral hygiene and remove bacterial deposits and calculus from the tooth and root surfaces.
Smoking is an important risk factor for periodontitis and may reduce the response to periodontal treatment by negatively affecting tissue healing. For this reason, additional treatments that may improve healing in smokers are being investigated. One of these approaches is the use of dental lasers together with conventional nonsurgical periodontal treatment.
Read more
The purpose of this study is to investigate whether adding Er,Cr:YSGG laser treatment to nonsurgical periodontal therapy improves treatment outcomes in systemically healthy smokers with Stage III periodontitis.
This study will use a split-mouth design, meaning that two different treatments will be compared within the same participant. One side of the mouth will receive conventional nonsurgical periodontal treatment, including scaling and root surface instrumentation. The other side will receive the same treatment together with Er,Cr:YSGG laser application. Changes in gum health, periodontal pocket depth, bone-related findings on radiographs, and biological markers related to bone metabolism will be evaluated during follow-up.
The study hypothesis is that adding Er,Cr:YSGG laser treatment to conventional nonsurgical periodontal therapy will provide additional clinical, radiographic, and biochemical benefits compared with conventional nonsurgical periodontal therapy alone in smokers with Stage III periodontitis.
Read the detailed description
Periodontitis is a chronic multifactorial inflammatory disease associated with dental biofilm and characterized by progressive destruction of the tooth-supporting tissues, including clinical attachment loss and alveolar bone loss. Smoking is an important modifiable risk factor for periodontitis and may adversely affect the host inflammatory response, periodontal wound healing, and bone metabolism. In the 2017 classification of periodontal diseases, smoking is considered an important modifier in determining the grade of periodontitis.
Non-surgical periodontal therapy is the first-line approach for controlling periodontal inflammation through disruption and removal of subgingival biofilm and calculus. However, complete instrumentation may be difficult in deep periodontal pockets and anatomically complex areas. These limitations have led to the investigation of adjunctive treatment approaches that may enhance the clinical and biological response to conventional non-surgical periodontal therapy.
Erbium lasers have been investigated as adjunctive tools in periodontal treatment because of their interaction with water-containing soft and hard tissues and their ability to ablate periodontal tissues and calculus with limited thermal damage when appropriate parameters are used. The Er,Cr:YSGG laser may provide additional effects through pocket decontamination, removal of diseased pocket epithelium and granulation tissue, root surface treatment, and modulation of the local healing environment.
Periodontal treatment response may also be evaluated using biological markers associated with bone remodeling. Receptor activator of nuclear factor-kappa B ligand (RANKL) promotes osteoclast differentiation and bone resorption, whereas osteoprotegerin (OPG) acts as a decoy receptor for RANKL and inhibits osteoclast activation. Sclerostin is an osteocyte-derived protein involved in the regulation of bone formation. Assessment of these biomarkers in gingival crevicular fluid may provide additional information regarding the biological response to periodontal treatment. In addition, radiographic fractal analysis may provide a quantitative assessment of trabecular bone architecture that may not be reflected by conventional linear bone measurements.
This randomized split-mouth clinical trial evaluates the adjunctive effect of Er,Cr:YSGG laser therapy in smokers with Stage III Grade C periodontitis. Contralateral regions are selected as test and control sites to reduce the influence of interindividual factors such as smoking exposure, host response, and oral hygiene behavior. Both sides receive non-surgical periodontal therapy, while the test side additionally receives Er,Cr:YSGG laser treatment according to a standardized periodontal protocol.
Treatment response is assessed using clinical periodontal measurements together with gingival crevicular fluid biomarkers and standardized radiographic analyses during follow-up. The combined evaluation of clinical, biochemical, and radiographic changes is intended to provide a multidimensional assessment of the possible adjunctive effects of Er,Cr:YSGG laser therapy in a high-risk periodontal population.
The aim of this randomized split-mouth clinical trial is to evaluate the adjunctive effects of Er,Cr:YSGG laser therapy on clinical periodontal parameters, gingival crevicular fluid biomarkers related to bone metabolism, and radiographic bone changes in smokers with Stage III Grade C periodontitis receiving non-surgical periodontal therapy. The study hypothesis is that adjunctive Er,Cr:YSGG laser therapy will produce differences in clinical, biochemical, and radiographic outcomes compared with non-surgical periodontal therapy alone.
- Conditions
- Periodontitis (Stage 3)
- Being tested
- Nonsurgical Periodontal Therapy, Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser
- Keywords
- periodontal debridement, Erbium; Laser therapy, RANK ligand, Sclerostin, Osteoprotegerin, smoking
- Medical subject headings
- Periodontitis, Sclerosteosis, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nonsurgical Periodontal TherapyProcedure or surgery
Nonsurgical periodontal therapy will consist of oral hygiene instructions followed by supra- and subgingival scaling and root surface instrumentation. Periodontal instrumentation will be performed using ultrasonic and hand instruments as required until the root surfaces are considered adequately debrided. No adjunctive laser treatment will be applied to sites allocated to the control side.
Nonsurgical Periodontal Therapy + Er,Cr:YSGG LaserProcedure or surgery
Following nonsurgical periodontal therapy, sites allocated to the experimental side will receive adjunctive Er,Cr laser treatment. The laser will be applied into the periodontal pockets according to a standardized protocol using predefined laser parameters and an appropriate periodontal tip. Laser irradiation will be performed along the treated periodontal pocket sites as an adjunct to conventional scaling and root surface instrumentation.
| Study group | Role | What they receive |
|---|---|---|
| Nonsurgical Periodontal Therapy | Active comparator | Participants will receive nonsurgical periodontal therapy consisting of scaling and root surface instrumentation on the sites allocated to the control side. No adjunctive laser treatment will be applied to these sites. Receives: Procedure: Nonsurgical Periodontal Therapy |
| Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser | Experimental | Participants will receive nonsurgical periodontal therapy consisting of scaling and root surface instrumentation on the sites allocated to the experimental side, followed by adjunctive Er,Cr:YSGG laser application. Receives: Procedure: Nonsurgical Periodontal Therapy; Procedure: Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Clinical Attachment Level
Clinical attachment level was measured in millimeters from the cementoenamel junction to the base of the periodontal pocket using a periodontal probe. Higher values indicate greater periodontal attachment loss. A reduction in clinical attachment level from baseline indicates clinical attachment gain and periodontal improvement.
Measured: Baseline, 6 weeks, 3 months, 6 months, 9 months, and 12 months
Secondary outcomes (1)
Change in Probing Pocket Depth
Measured: Baseline, 6 weeks, 3 months, 6 months, 9 months, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start1 Feb 2025
- Primary completion1 Aug 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Periodontitis (Stage 3)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Okan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gökçe Aykol Şahin, Okan University
- Investigators
- Gokce Aykol Sahin, PhD, Study director, Okan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07851584
- Sponsor's protocol ID
- 668
- Other IDs
- E-61749811-000-2805802
- Status last verified
- Sep 2026
- First submitted
- 25 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the main results of the study are planned to be made available from the corresponding author upon reasonable request after completion of the study and publication of the main results.
Publications
Park JS, Jung H, Ryu JJ, Koo KT, Lee J. Effect of erbium, chromium-doped: yttrium, scandium, gallium, and garnet laser-assisted periodontal therapy using radial firing tip during early healing period: a randomized controlled split-mouth clinical trial. BMC Oral Health. 2024 May 8;24(1):539. doi: 10.1186/s12903-024-04270-1.
PubMed 38720276Updike SX, Nowzari H. Fractal analysis of dental radiographs to detect periodontitis-induced trabecular changes. J Periodontal Res. 2008 Dec;43(6):658-64. doi: 10.1111/j.1600-0765.2007.01056.x. Epub 2008 Jun 24.
PubMed 18624949Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-kappaB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.
PubMed 26367496Belibasakis GN, Bostanci N. The RANKL-OPG system in clinical periodontology. J Clin Periodontol. 2012 Mar;39(3):239-48. doi: 10.1111/j.1600-051X.2011.01810.x. Epub 2011 Oct 24.
PubMed 22092994Klokkevold PR, Damian A, Pham C, Mallya SM, Lux R. Clinical evaluation of Er,Cr:YSGG laser therapy used as an adjunct to non-surgical treatment of periodontitis: Twelve-month results from a pilot study. J Periodontol. 2022 Sep;93(9):1314-1324. doi: 10.1002/JPER.21-0443. Epub 2022 Mar 24.
PubMed 35239185Cobb CM. Lasers in periodontics: a review of the literature. J Periodontol. 2006 Apr;77(4):545-64. doi: 10.1902/jop.2006.050417.
PubMed 16584335Suvan J, Leira Y, Moreno Sancho FM, Graziani F, Derks J, Tomasi C. Subgingival instrumentation for treatment of periodontitis. A systematic review. J Clin Periodontol. 2020 Jul;47 Suppl 22:155-175. doi: 10.1111/jcpe.13245.
PubMed 31889320Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.
PubMed 32383274Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Clin Periodontol. 2018 Jun;45 Suppl 20:S149-S161. doi: 10.1111/jcpe.12945.
PubMed 29926495Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF, Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A, Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi: 10.1002/JPER.17-0721.
PubMed 29926951
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical, Radiographic, and Biochemical Outcomes of Er,Cr:YSGG Laser-Assisted Nonsurgical Periodontal Therapy in Smokers With Stage III Grade C Periodontitis: A Split-Mouth Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07851584
- Acronym / sponsor ID
- 668
- Conditions
- Periodontitis (Stage 3)
- Keywords
- periodontal debridement, Erbium; Laser therapy, RANK ligand, Sclerostin, Osteoprotegerin, smoking
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Okan UniversityUniversity, hospital or other
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 1 Aug 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontitis is an inflammatory disease that affects the tissues supporting the teeth. If the disease progresses, it can cause loss of the tissues and bone around the teeth and lead to the formation of deep spaces, called periodontal pockets, between the teeth and gums. The main treatment for periodontitis is to improve oral hygiene and remove bacterial deposits and calculus from the tooth and root surfaces.
Smoking is an important risk factor for periodontitis and may reduce the response to periodontal treatment by negatively affecting tissue healing. For this reason, additional treatments that may improve healing in smokers are being investigated. One of these approaches is the use of dental lasers together with conventional nonsurgical periodontal treatment.
The purpose of this study is to investigate whether adding Er,Cr:YSGG laser treatment to nonsurgical periodontal therapy improves treatment outcomes in systemically healthy smokers with Stage III periodontitis.
This study will use a split-mouth design, meaning that two different treatments will be compared within the same participant. One side of the mouth will receive conventional nonsurgical periodontal treatment, including scaling and root surface instrumentation. The other side will receive the same treatment together with Er,Cr:YSGG laser application. Changes in gum health, periodontal pocket depth, bone-related findings on radiographs, and biological markers related to bone metabolism will be evaluated during follow-up.
The study hypothesis is that adding Er,Cr:YSGG laser treatment to conventional nonsurgical periodontal therapy will provide additional clinical, radiographic, and biochemical benefits compared with conventional nonsurgical periodontal therapy alone in smokers with Stage III periodontitis.
Detailed description
Periodontitis is a chronic multifactorial inflammatory disease associated with dental biofilm and characterized by progressive destruction of the tooth-supporting tissues, including clinical attachment loss and alveolar bone loss. Smoking is an important modifiable risk factor for periodontitis and may adversely affect the host inflammatory response, periodontal wound healing, and bone metabolism. In the 2017 classification of periodontal diseases, smoking is considered an important modifier in determining the grade of periodontitis.
Non-surgical periodontal therapy is the first-line approach for controlling periodontal inflammation through disruption and removal of subgingival biofilm and calculus. However, complete instrumentation may be difficult in deep periodontal pockets and anatomically complex areas. These limitations have led to the investigation of adjunctive treatment approaches that may enhance the clinical and biological response to conventional non-surgical periodontal therapy.
Erbium lasers have been investigated as adjunctive tools in periodontal treatment because of their interaction with water-containing soft and hard tissues and their ability to ablate periodontal tissues and calculus with limited thermal damage when appropriate parameters are used. The Er,Cr:YSGG laser may provide additional effects through pocket decontamination, removal of diseased pocket epithelium and granulation tissue, root surface treatment, and modulation of the local healing environment.
Periodontal treatment response may also be evaluated using biological markers associated with bone remodeling. Receptor activator of nuclear factor-kappa B ligand (RANKL) promotes osteoclast differentiation and bone resorption, whereas osteoprotegerin (OPG) acts as a decoy receptor for RANKL and inhibits osteoclast activation. Sclerostin is an osteocyte-derived protein involved in the regulation of bone formation. Assessment of these biomarkers in gingival crevicular fluid may provide additional information regarding the biological response to periodontal treatment. In addition, radiographic fractal analysis may provide a quantitative assessment of trabecular bone architecture that may not be reflected by conventional linear bone measurements.
This randomized split-mouth clinical trial evaluates the adjunctive effect of Er,Cr:YSGG laser therapy in smokers with Stage III Grade C periodontitis. Contralateral regions are selected as test and control sites to reduce the influence of interindividual factors such as smoking exposure, host response, and oral hygiene behavior. Both sides receive non-surgical periodontal therapy, while the test side additionally receives Er,Cr:YSGG laser treatment according to a standardized periodontal protocol.
Treatment response is assessed using clinical periodontal measurements together with gingival crevicular fluid biomarkers and standardized radiographic analyses during follow-up. The combined evaluation of clinical, biochemical, and radiographic changes is intended to provide a multidimensional assessment of the possible adjunctive effects of Er,Cr:YSGG laser therapy in a high-risk periodontal population.
The aim of this randomized split-mouth clinical trial is to evaluate the adjunctive effects of Er,Cr:YSGG laser therapy on clinical periodontal parameters, gingival crevicular fluid biomarkers related to bone metabolism, and radiographic bone changes in smokers with Stage III Grade C periodontitis receiving non-surgical periodontal therapy. The study hypothesis is that adjunctive Er,Cr:YSGG laser therapy will produce differences in clinical, biochemical, and radiographic outcomes compared with non-surgical periodontal therapy alone.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nonsurgical Periodontal Therapy | Active comparator | Procedure: Nonsurgical Periodontal TherapyParticipants will receive nonsurgical periodontal therapy consisting of scaling and root surface instrumentation on the sites allocated to the control side. No adjunctive laser treatment will be applied to these sites. |
| Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser | Experimental | Procedure: Nonsurgical Periodontal Therapy, Procedure: Nonsurgical Periodontal Therapy + Er,Cr:YSGG LaserParticipants will receive nonsurgical periodontal therapy consisting of scaling and root surface instrumentation on the sites allocated to the experimental side, followed by adjunctive Er,Cr:YSGG laser application. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age between 35 and 65 years
- Systemically healthy status
- Smoking ≥10 cigarettes/day for at least 5 years
- Diagnosis of Stage III Grade C periodontitis according to the 2017 classification
- Stage III classification based on periodontal tissue destruction, with interdental clinical attachment loss ≥5 mm
Key exclusion criteria (10 listed)
- Systemic disease or condition affecting periodontal status, wound healing, or bone metabolism
- Pregnancy or lactation
- Non-smoker or smoking <10 cigarettes/day
- Gingivitis
- Stage I, Stage II, or Stage IV periodontitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nonsurgical Periodontal TherapyNonsurgical periodontal therapy will consist of oral hygiene instructions followed by supra- and subgingival scaling and root surface instrumentation. Periodontal instrumentation will be performed using ultrasonic and hand instruments as required until the root surfaces are considered adequately debrided. No adjunctive laser treatment will be applied to sites allocated to the control side. | Procedure or surgery | Nonsurgical Periodontal Therapy, Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser |
| Nonsurgical Periodontal Therapy + Er,Cr:YSGG LaserFollowing nonsurgical periodontal therapy, sites allocated to the experimental side will receive adjunctive Er,Cr laser treatment. The laser will be applied into the periodontal pockets according to a standardized protocol using predefined laser parameters and an appropriate periodontal tip. Laser irradiation will be performed along the treated periodontal pocket sites as an adjunct to conventional scaling and root surface instrumentation. | Procedure or surgery | Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser |
Primary outcome
Change in Clinical Attachment Level
Time frame: Baseline, 6 weeks, 3 months, 6 months, 9 months, and 12 months
Clinical attachment level was measured in millimeters from the cementoenamel junction to the base of the periodontal pocket using a periodontal probe. Higher values indicate greater periodontal attachment loss. A reduction in clinical attachment level from baseline indicates clinical attachment gain and periodontal improvement.
1 secondary outcome
Change in Probing Pocket Depth
Time frame: Baseline, 6 weeks, 3 months, 6 months, 9 months, and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Background: PubMed 38720276Park JS, Jung H, Ryu JJ, Koo KT, Lee J. Effect of erbium, chromium-doped: yttrium, scandium, gallium, and garnet laser-assisted periodontal therapy using radial firing tip during early healing period: a randomized controlled split-mouth clinical trial. BMC Oral Health. 2024 May 8;24(1):539. doi: 10.1186/s12903-024-04270-1.
- Background: PubMed 18624949Updike SX, Nowzari H. Fractal analysis of dental radiographs to detect periodontitis-induced trabecular changes. J Periodontal Res. 2008 Dec;43(6):658-64. doi: 10.1111/j.1600-0765.2007.01056.x. Epub 2008 Jun 24.
- Background: PubMed 26367496Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-kappaB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.
- Background: PubMed 22092994Belibasakis GN, Bostanci N. The RANKL-OPG system in clinical periodontology. J Clin Periodontol. 2012 Mar;39(3):239-48. doi: 10.1111/j.1600-051X.2011.01810.x. Epub 2011 Oct 24.
- Background: PubMed 35239185Klokkevold PR, Damian A, Pham C, Mallya SM, Lux R. Clinical evaluation of Er,Cr:YSGG laser therapy used as an adjunct to non-surgical treatment of periodontitis: Twelve-month results from a pilot study. J Periodontol. 2022 Sep;93(9):1314-1324. doi: 10.1002/JPER.21-0443. Epub 2022 Mar 24.
- Background: PubMed 16584335Cobb CM. Lasers in periodontics: a review of the literature. J Periodontol. 2006 Apr;77(4):545-64. doi: 10.1902/jop.2006.050417.
- Background: PubMed 31889320Suvan J, Leira Y, Moreno Sancho FM, Graziani F, Derks J, Tomasi C. Subgingival instrumentation for treatment of periodontitis. A systematic review. J Clin Periodontol. 2020 Jul;47 Suppl 22:155-175. doi: 10.1111/jcpe.13245.
- Background: PubMed 32383274Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.
- Background: PubMed 29926495Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Clin Periodontol. 2018 Jun;45 Suppl 20:S149-S161. doi: 10.1111/jcpe.12945.
- Background: PubMed 29926951Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF, Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A, Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi: 10.1002/JPER.17-0721.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the main results of the study are planned to be made available from the corresponding author upon reasonable request after completion of the study and publication of the main results.
Related trials for Periodontitis (Stage 3)
RecruitingObservational study
Characterization of Small Intestinal Bacterial Overgrowth and Intestinal Barrier-Related Biomarkers in Patients With Severe Periodontitis
Periodontitis (Stage 3), Periodontitis Stage IV
Recruiting
A Clinical Trial Comparing 2x/Day for 30-minutes Use of the Emanate Perio PODS Post-SRP to a Control Group Post-SRP.
Periodontitis (Stage 3)
Active, not recruitingObservational study
Evaluation of the Effect of Smoking on Apelin, Periostin, and High-Sensitivity CRP Levels in Gingival Crevicular Fluid and Serum
Periodontitis (Stage 3), Periodontal Health
Recruiting
Active Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis
Stage III Periodontitis
Recruiting
Dental Loupe Versus Dental Operating Microscope for Non-Surgical Periodontal Treatment
Periodontitis, Periodontitis and Treatment Need
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gokce Aykol Sahin, PhD study director
Okan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nonsurgical Periodontal Therapy and Nonsurgical Periodontal Therapy + Er,Cr:YSGG Laser in people with Periodontitis (Stage 3), run by Okan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Clinical Attachment Level (time frame: Baseline, 6 weeks, 3 months, 6 months, 9 months, and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07851584, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.